We are excited to announce that we are now Calibr-Skaggs Institute for Innovative Medicine, and we remain a division of Scripps Research. Press release: https://lnkd.in/e6DRe2fA We are also excited to announce our new website! Please have a look: https://lnkd.in/gjHU84zA #nonprofit #drugdevelopment #pipeline
Calibr-Skaggs Institute for Innovative Medicines
Biotechnology Research
San Diego, CA 4,788 followers
Translating groundbreaking scientific discoveries into major therapeutic advances
About us
The Calibr-Skaggs Institute for Innovative Medicines is a pioneering translational research institute dedicated to accelerating the next generation of medicines for critical unmet needs. We are a leading nonprofit drug discovery engine bringing treatments from discovery into the clinic across multiple disease areas. As a division of Scripps Research—the largest private, nonprofit biomedical research organization in the United States ranked for its impact on innovation—we leverage a wide range of world-renowned, pioneering scientific approaches and technologies. Our self-sustaining model encourages bold exploration of ideas with far-reaching impact, while facilitating the transition of these ideas into clinical development.
- Website
-
http://calibr.scripps.edu
External link for Calibr-Skaggs Institute for Innovative Medicines
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Nonprofit
- Founded
- 2012
Locations
-
Primary
11119 N Torrey Pines Rd
San Diego, CA 92037, US
Employees at Calibr-Skaggs Institute for Innovative Medicines
-
Chan Beals
Chief Medical Officer
-
Vincent Davis
-
Mary Sullivan, Ph.D.
VP, Corporate Development at Calibr at Scripps Research || Formerly L.E.K. Consulting, Yale
-
Sumit Chanda
Professor, Department of Immunology and Microbiology, Scripps Research. Senior Principal Investigator, Calibr.
Updates
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
Can we repurpose existing drugs to fight global health challenges like HIV, malaria, tuberculosis and pandemic threats? In our latest Front Row lecture, Arnab Chatterjee, PhD, shared how the Calibr-Skaggs Institute for Innovative Medicines—the drug discovery and development arm of Scripps Research— is leading this effort. Using the ReFRAME drug-repurposing library, Chatterjee’s team rapidly screens thousands of safe drugs to uncover new treatments for underserved diseases. He also discussed long-acting injectables that could transform HIV care by reducing treatment to once every three months. Watch the full lecture and explore the key takeaways: https://ow.ly/4AU850ThLTn
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
Very thankful to talk about pandemic preparedness and open access tools developed Calibr-Skaggs Institute for Innovative Medicines with Bill & Melinda Gates Foundation support like the reframedb.org drug repurposing library to expedite drug development timelines to the clinic!
Communities around the world are facing ever-growing challenges with infectious diseases like tuberculosis and malaria due to a lack of investment, long-term protocols, and drug resistance. Next week at our free Front Row lecture, vice president of medicinal chemistry Arnab Chatterjee will discuss how the Calibr-Skaggs Institute for Innovative Medicines—the drug discovery and development arm of Scripps Research—is using innovative new approaches and technologies to overcome these historic barriers. His work at the Calibr-Skaggs Institute is helping accelerate the delivery of safe, effective and accessible medicines to countries spanning the globe. Reserve your seat now: https://ow.ly/C97n50SY1vR
-
🌟 **Front Row Lecture at Scripps Research: A Deep Dive into Regenerative Medicine** 🌟 A few weeks ago, Dr. Michael Bollong at Scripps Research gave an insightful Front Row Lecture. Please watch at the link below if you haven't! Dr. Bollong, a leading figure in regenerative medicine, shared groundbreaking developments from his lab’s pioneering work on drug development aimed at regenerating lung and heart tissues, as well as his vision of tackling diseases of aging. This remarkable research, some of which has been advanced at Calibr-Skaggs Institute for Innovative Medicines, showcases the innovative approaches being explored to address critical health challenges. Dr. Bollong's presentation highlighted the promising strides his team has made in creating therapies that could potentially transform the treatment of damaged tissues and improve patient outcomes. A big thank you to Dr. Bollong for his exceptional presentation and to all who attended. This is a thrilling time for regenerative medicine, and we look forward to seeing how these advancements will continue to evolve and impact the future of human health and aging. #RegenerativeMedicine #DrugDevelopment #ScrippsResearch #CalibrSkaggs #Innovation https://lnkd.in/e5_ueQg6
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
Save the date! If you are interested in learning what Scripps Research is doing to help accelerate the delivery of safe, effective, and accessible medicines for a #global population, join us at our next Front Row event: Wednesday, August 21, 2024 4:00 p.m. PT | 7:00 p.m. ET Listen to Arnab Chatterjee, Vice President of Medicinal Chemistry here at Scripps, who will discuss how the Calibr-Skaggs Institute for Innovative Medicine at Scripps is using innovative new approaches and technologies to overcome historical barriers to curing tuberculosis and malaria, among other illnesses, around the world. Register for this free event here: https://lnkd.in/g92pShxt #Chemistry #medicine #innovation #technology #tuberculosis #malaria
Delivering medicines for a global population: Arnab Chatterjee, PhD - Scripps Research
https://frontrow.scripps.edu
-
🎙️ Engaging Podcast on Pandemic Preparedness Check out this thought-provoking conversation between Arnab Chatterjee and Lauren Fish on our latest podcast episode. They discuss groundbreaking work being done at Calibr-Skaggs and Scripps to prepare for future viral threats. Discover the innovative strategies and research efforts that are shaping the future of global health security. Whether you’re in the field or simply interested in how we can be better prepared for the next pandemic, this episode is a must-listen. #PandemicPreparedness #GlobalHealth #Innovation
Are we facing a new pandemic threat? Arnab Chatterjee, vice president of medicinal chemistry at Calibr-Skaggs Institute for Innovative Medicines, discusses the challenges of viral mutation, the innovative solutions antivirals provide, and the strategies to combat the mutating H5N1 virus. Listen to the full episode of "Arnab Chatterjee: What we know about H5N1 bird flu" now: https://ow.ly/LBnv50SPpkC
-
Calibr-Skaggs is on the lookout for an exceptionally talented Associate Director to lead our protein sciences team within the biologics drug discovery group. If you have a passion for innovation and leadership, this is your chance to make a significant impact in the field of drug discovery! Join us in pioneering advancements in immuno-oncology, immunology, infectious and neglected tropical diseases, metabolic disorders, neuro, and rare disease indications. Ready to take the lead in groundbreaking research? Apply now at Calibr-Skaggs! https://lnkd.in/gPHgsdYG #DrugDiscovery #Leadership #Innovation #ProteinSciences #CareerOpportunity
recruiting2.ultipro.com
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
A new study published in Science Magazine, led by Scripps Research Prof. John Teijaro, PhD, has discovered a powerful combination therapy that boosts the effectiveness of cancer treatments. The team found that combining ruxolitinib, an approved immunosuppressive drug, with checkpoint inhibitors supercharges T-cell responses. “It's very rare to have supporting evidence with preclinical data and a clinical trial in one paper,” says Teijaro. “Our results are particularly exciting because we are already seeing patients benefit from the combination and we believe this could be applied to several immunotherapy resistant cancers.” Read the full press release: https://ow.ly/tbEK50SmNsL
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
Following last week’s announcement of MMV’s 2023 Project of the Year, a novel compound that holds the potential to cure patients, prevent infections and counter drug resistance, we sat down with the two project leads from MMV and Calibr-Skaggs Institute for Innovative Medicines to learn more about their process, how partnering across organizations can facilitate drug development and more. Read the entire interview with Calibr-Skaggs’ Director of Medical Chemistry, Dr Anil Gupta, and MMV’s Senior Director of Drug Discovery, Dr James Duffy: bit.ly/MMV_PoY
-
Calibr-Skaggs Institute for Innovative Medicines reposted this
This week, MMV’s Expert Scientific Advisory Committee (ESAC) awarded the 2023 Project of the Year to a discovery team led by Dr Anil Gupta, Director of Medical Chemistry for the Calibr-Skaggs Institute for Innovative Medicines and Dr James Duffy, Senior Director of Drug Discovery for MMV. The award recognizes the team’s discovery of CMQ069, a compound that may help expand the antimalarial toolbox, thanks to its potency on multiple stages of the malaria parasite lifecycle. As a novel compound with potential for low-dose treatment, CMQ069 could provide an alternative to the current artemisinin-based therapies for which partial drug resistance has been detected in Asia and more recently in Africa. CMQ069 may also have the capacity to meet the oral chemoprevention goal of protective efficacy following a single monthly oral dose. Congratulations to Dr Anil Gupta, Dr Arnab Chatterjee, Dr Case McNamara, Dr Jenya (Yevgeniya) Antonova-Koch and Dr Peter Schultz from the project team at Calibr-Skaggs, and Dr James Duffy, Dr Anne Cooper and Dr Peter Webborn at MMV for this recognition of scientific excellence! Learn more about this project and the CMQ069 compound: bit.ly/MMV_PoY24